化疗联合芳香化酶抑制剂治疗绝经后激素受体阳性乳腺癌患者的临床效果及安全性分析
Analysis on Clinical Effect and Safety of Chemotherapy Combined with Aromatase Inhibitor in the Treatment of Patients with Postmenopausal Positive Hormone Receptor Breast Cancer
谭要鹏 1李平 1刘超颖1
作者信息
- 1. 许昌市中心医院乳腺外科,河南许昌 461000
- 折叠
摘要
目的 分析化疗联合芳香化酶抑制剂治疗绝经后激素受体阳性乳腺癌患者的临床效果及安全性.方法 选取 2020 年2 月至 2022 年 6 月我院收治的 90 例绝经后激素受体阳性乳腺癌患者,随机分为参照组(45 例)和联合组(45 例).参照组予以TE(多西他赛+表柔比星)化疗,联合组在参照组基础上予以阿那曲唑治疗,比较两组患者的客观缓解率(ORR)及不良反应发生率.结果 联合组ORR为 55.56%,明显高于参照组的 33.33%(P＜0.05).联合组治疗期间不良反应发生率为 31.11%,与参照组的 37.78%比较差异无统计学意义(P＞0.05).结论 化疗联合芳香化酶抑制剂治疗绝经后激素受体阳性乳腺癌患者,可明显提升临床疗效,但未明显增加患者不良反应的发生,安全性较高.
Abstract
Objective To analyze the clinical effect and safety of chemotherapy combined with aromatase inhibitor in the treatment of patients with postmenopausal positive hormone receptor breast cancer.Methods 90 patients with postmenopausal positive hormone receptor breast cancer admitted to our hospital from February 2020 to June 2022 were selected and randomly divided into reference group(45 cases)and combined group(45 cases).The reference group was treated with TE(docetaxel+epirubicin)chemotherapy,and the combined group was treated with anastrozole on the basis of the reference group.The objective response rate(ORR)and the incidence of adverse reactions were compared between the two groups.Results The ORR of the combined group was 55.56%,significantly higher than 33.33%of the reference group(P<0.05).During the treatment,the incidence of adverse reactions in the combined group was 31.11%,which had no statistical difference with 37.78%in the reference group(P>0.05).Conclusions Chemotherapy combined with aromatase inhibitor in the treatment of patients with postmenopausal positive hormone receptor breast cancer,can significantly improve the clinical efficacy,but does not significantly increase the incidence of adverse reactions with higher safety.
关键词
乳腺癌/激素受体阳性/芳香化酶抑制剂/化疗/临床疗效/安全性Key words
Breast cancer/Positive hormone receptor/Aromatase inhibitor/Chemotherapy/Clinical efficacy/Safety引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据